Subhash C. Sinha

This study identifies five novel UBA5 inhibitors through HTS, showing selectivity and efficacy in inhibiting UFMylation, with potential for therapeutic applications in neurodegenerative diseases and cancer.

This study identifies LINE-1 retrotransposons as drivers of neuronal senescence in Alzheimer's disease through cytoplasmic DNA sensing and the cGAS-STING pathway.

This study identifies cGAS as a key mediator of TDP-43 pathology in ALS and shows that its inhibition reduces RNA splicing defects and neurodegeneration.

This study identifies cGAS-mediated IFN-I signaling as a driver of disease progression in drug-refractory epilepsy, showing that targeting cGAS reduces epileptic phenotypes and inflammation.

The paper identifies a potent human cGAS inhibitor through high-throughput screening and SAR analysis, showing sub-micromolar activity and partial inhibition of cGAMP levels.

The paper investigates how structurally diverse imatinib analogs affect APP metabolism similarly, identifying potent isomers for further development.

This study combines APOE4 and TREM2R47H in female tauopathy mice to identify pathways activated by AD risk factors, finding cGAS-STING signaling and microglial senescence as potential drivers.

The R136S mutation on APOE3 enhances resistance to tau-related pathology and toxicity by downregulating the cGAS-STING-IFN signaling pathway.

The paper identifies DEK as a driver of tau pathology in Alzheimer's disease vulnerable neurons using in silico modeling and experimental validation.